The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma, Sodium/Iodide Symporter Expression, and [BRAF.sup.V600E] Mutation

Objective: To study the association between radioiodine refractory papillary thyroid carcinoma, sodium/iodide symporter (NIS) expression, and the [BRAF.sup.V600E] mutation. Methods: A study was conducted on 30 radioiodine refractory papillary thyroid carcinoma patients and 30 radioiodine-avid papill...

Full description

Saved in:
Bibliographic Details
Published inOncoTargets and therapy Vol. 14; p. 3959
Main Authors Anekpuritanang, Tauangtham, Uataya, Maythad, Claimon, Apichaya, Laokulrath, Natthawadee, Pongsapich, Warut, Pithuksurachai, Paveena
Format Journal Article
LanguageEnglish
Published Dove Medical Press Limited 30.06.2021
Subjects
Cancer
Carcinoma
Formaldehyde
Gene mutations
Genetic aspects
Immunohistochemistry
Thyroid diseases
Thailand
Serbia
Online AccessGet full text

Cover

More Information
Summary:Objective: To study the association between radioiodine refractory papillary thyroid carcinoma, sodium/iodide symporter (NIS) expression, and the [BRAF.sup.V600E] mutation. Methods: A study was conducted on 30 radioiodine refractory papillary thyroid carcinoma patients and 30 radioiodine-avid papillary thyroid carcinoma patients. The expressions of sodium/iodide symporter and [BRAF.sup.V600E] mutated protein were determined by immunohistochemistry using formalin-fixed, paraffin-embedded tissue. Results: The mutated [BRAF.sup.V600E] protein was identified in 26 radioiodine refractory papillary thyroid carcinoma subjects (86.7%) and 22 radioiodine-avid papillary thyroid carcinoma subjects (73.3%), with no significant difference between the 2 groups (P = 0.3). Sodium/ iodide symporter expression was detected in 4 of 30 cases (13.3%) from the radioiodine-avid papillary thyroid carcinoma group but was negative for all radioiodine refractory cases. There was no association between sodium/iodide symporter expression and radioiodine refractory papillary thyroid carcinoma (P = 0.11). Cases with positive NIS expression were likely negative for [BRAF.sup.V600E] mutation (3/4; P = 0.02). Conclusion: Papillary thyroid carcinomas with [BRAF.sup.V600E] mutation were more likely to be negative for NIS expression. [BRAF.sup.V600E] mutation and NIS expressions cannot be used to predict radioiodine sensitivity. Keywords: BRAF mutation, immunohistochemistry, papillary thyroid carcinoma, radioiodine therapy, sodium/iodide symporter
ISSN:1178-6930
1178-6930
DOI:10.2147/OTT.S308910